Purpose of review HIV-associated cryptococcal meningitis remains a significant contributor to AIDS-related mortality despite widened access to antiretroviral therapy. Even in clinical trial settings 10-week mortality is roughly 40%. A number of important clinical trials have either recently concluded or are actively recruiting.
INTRODUCTION
HIV-associated cryptococcal meningitis remains a significant contributor to AIDS-related mortality globally, despite roll-out of antiretroviral therapy (ART) && ]. In this article, we discuss recent trends in the epidemiology of cryptococcal meningitis, innovation in diagnosis and screening, and discuss the findings of recently completed randomized controlled trials.
EPIDEMIOLOGY
A recent systematic review examining the global prevalence of cryptococcal antigenaemia (CrAg) in HIV-infected individuals with low CD4 cell counts found a pooled global CrAg prevalence of 6.5% in individuals with CD4 less than 100 cells/ml, and 2% among those with CD4 counts 101-200 cells/ml [5] . Updated global burden of disease estimates suggest there were approximately 278 000 HIV-infected people positive for CrAg, and an estimated 223 100 incident cases of cryptococcal meningitis globally in 2014, with 73% of these occurring in sub-Saharan Africa. Annual global deaths from cryptococcal meningitis were estimated at 181 100 ( Fig. 1) [ 1 & ]. Globally, cryptococcal meningitis is responsible for roughly 15% of AIDS-related deaths and is associated with significant long-term disability [6, 7] .
In Botswana, one of the first countries in subSaharan Africa to implement a country-wide ART programme, despite excellent ART coverage there is still a substantial burden of advanced HIV, with the 2013-2014 incidence of cryptococcal meningitis comparable with pre-ART era rates seen in South
Data from South Africa also show minimal or no recent decline in the number of cryptococcal meningitis cases with widespread ART roll out [9] . This is likely to result from increasing numbers of patients on long-term ART interrupting, stopping, or failing therapy, offsetting any decline in the numbers of patients presenting for the first time with advanced HIV-disease. The number of patients in South Africa with a CD4 less than 100 cells/ml and the proportion of those who are CrAgpositive does not appear to have changed in recent years, however 51% of patients with a CD4 less than 50 cells/ml are now ART experienced [9, 10] . Similarly, in Kampala, Uganda, 59% of patients presenting with cryptococcal meningitis are now ART experienced [11] . These studies highlight the growing complexity of cryptococcal meningitis patients who often have ART resistance and difficulty with adherence.
DIAGNOSTICS
Although the gold standard for cryptococcal meningitis diagnosis remains a positive cryptococcus cerebrospinal fluid (CSF) culture, the current mainstay of cryptococcal diagnosis is the detection of CrAg, a polysaccharide of the cryptococcal capsule which is shed in CSF and blood (Fig. 2) . Cryptococcal meningitis diagnosis has been revolutionized by the widespread availability of reliable point-of-care Lateral Flow Assays (LFAs) which detect CrAg. The IMMY LFA remains the most sensitive and specific rapid diagnostic test (RDT) available [12] . A potential substitute to the IMMY LFA, the StrongStep, was found to
KEY POINTS
Cryptococcal meningitis remains a significant cause of AIDS-associated mortality.
Treatment with conventional 14-day courses of amphotericin are associated with high toxicity and mortality and can be reduced to 7 days if given alongside flucytosine.
Flucytosine is a significantly superior adjunct to amphotericin treatment compared with fluconazole.
A single, high-dose of liposomal amphotericin is effective at reducing fungal burden and is being tested in a phase III trial. Emerging concepts in HIV-associated cryptococcal meningitis Lawrence et al. [14] . A study in Uganda has shown that acridine orange, which stains fungal nucleic acids rather than the capsule, was more sensitive than India ink (96 vs. 69%) with reference to CrAg [14] .
Cryptococcal colony forming units (CFUs) can be counted on serially diluted samples of CSF to enable the quantification of fungal burden, and have been shown to be a strong prognostic indicator [15] .
However, such quantitative cultures are time consuming and difficult to perform, hence alternatives methods to rapidly assess fungal burden are needed. Trypan blue staining and automated cell counting using the TC20 automated cell counter has been evaluated in Uganda, but found to be poorly predictive of quantitative CFU counts [16] . Flow cytometry using a BD LSRFortessa (BD Biosciences, San Jose, California, USA) flow cytometer did provide a rapid and accurate measurement of fungal burden in patients with cryptococcal meningitis in a small pilot study in South Africa [17] , providing proof or principle for the technique, and if combined with a cryptococcal viability stain [18] , could potentially be used to assess the response to treatment. Another alternative to quantitative culture is a quantitative PCR test for cryptococcus in both blood and CSF being developed by researchers at the Institut Pasteur. 
PREVENTION
CrAg can be detected in the blood many weeks before the onset of cryptococcal meningitis symptoms [19] . WHO guidelines recommended CrAg screening as the preferred cryptococcal meningitis prevention strategy in all patients with a CD4 less than 100 cells/ml [20 && ]. Patients who test positive for serum CrAg should be screened for symptoms of cryptococcal meningitis, and ideally offered a lumbar puncture even in the absence of meningitis symptoms. In cases where patients decline a lumbar puncture, and for all patients without evidence of meningitis, high-dose preemptive fluconazole (800-1200 mg/day) is recommended for 2 weeks followed by standard fluconazole consolidation and maintenance treatment [20 && ]. The importance of performing CSF analysis to identify patients in need of more intensive treatment was highlighted in a recent South African study showing that 34% of asymptomatic CrAg positive patients had cryptococcal meningitis [21 & ]. A systematic review and meta-analysis of CrAg screening studies assessing the prevalence of asymptomatic cryptococcal meningitis in CrAg positive patients, the incidence of cryptococcal meningitis, and all-cause mortality rates, reported a pooled prevalence of asymptomatic cryptococcal meningitis in CrAg positive participants of 33% [95% confidence interval (CI), 21-45%]. The incidence of cryptococcal meningitis in CrAg positive individuals was 21.4% (95% CI, 11.6-34.4%) without preemptive fluconazole and 5.7% (95% CI, 3.0-9.7%) with preemptive fluconazole therapy initiated at 800 mg/day [22] .
National CrAg screening programmes have now been implemented in several African countries, with economic analyses suggesting the intervention should be cost-effective in African settings [23, 24] . However, early implementation has been challenging, with low rates of uptake when testing is left to the discretion of individual clinicians [25] , suggesting automatic, or 'reflex' screening of CD4 samples with low CD4 counts is preferable. Even with reflex screening strategies, losses to follow-up or delays in receiving and acting on CrAg results can adversely impact the effectiveness of the intervention [26] . Point of care CrAg testing may avoid these losses and delays [27] , and the IMMY CrAg assay can be performed effectively on finger prick blood samples [28] . In settings where CrAg screening is not possible, primary fluconazole prophylaxis remains an option for cryptococcal meningitis prevention in individuals with advanced HIV-disease [20 && ], with recent data confirming its effectiveness in reducing the incidence of cryptococcal disease [29] . (Fig. 3) . Among those taking flucytosine as the partner drug, 7 days of amphotericin B had lower 10-week mortality (24%, 95% CI: 16-32%) compared with 14 days of amphotericin B and flucytosine (38%, 95% CI: 29-32%, hazard ratio 0.56, 95% CI: 0.35-0.91). Notably, the poorest performing arm of the ACTA trial was 7 days amphotericin B and fluconazole, so a reduction from 14 to 7 days of amphotericin B is only possible in contexts where flucytosine is available. One week of amphotericin B was associated with less druginduced toxicity, a reduced need for laboratory monitoring, shorter hospital admissions and fewer adverse effects such as anaemia requiring blood transfusions. ACTA also confirmed that flucytosine is a significantly superior partner drug for amphotericin B-based treatments, leading to a substantial mortality reduction of 38% (95% CI: 16-55%, P ¼ 0.002) compared with fluconazole. The oral combination arm (fluconazole and flucytosine) was the second best performing arm with a 10-week mortality of 35% (95% CI 29-41%). In light of these trial data, and a subsequent Cochrane review [30 & ], updated WHO guidelines recommended first-line induction treatment of 7 days of amphotericin B and flucytosine 100 mg/kg/day, followed by 7 days of fluconazole 1200 mg/day (Table 1) [20 && ]. In high-income settings, an alternative induction regimen is 14 days of liposomal amphotericin (L-AmB) and flucytosine [31] . L-AmB is associated with fewer drug-induced toxicities than the standard deoxycholate formulation, and well suited for use in short-course induction treatment due to the potential for high dosing made possible by the lower rates of toxicity, the long tissue half-life and its effective penetration into brain tissue [32] . The recently completed AMBITION phase II trial was performed with the primary objective of determining the rate of clearance of cryptococcus from the cerebrospinal fluid, the early fungicidal activity (EFA), of three alternative schedules of intermittent high-dose L-AmB in comparison with standard daily L-AmB [4 && ]. Eighty participants were recruited at sites in Botswana and Tanzania and randomized to one of four treatment arms: first, L-AmB 10 mg/kg day 1 (single dose); second, L-AmB 10 mg/kg day 1, L-AmB 5 mg/kg day 3 (two doses); third, L-AmB 10 mg/kg day 1, L-AmB 5 mg/kg days 3 and 7 (three doses). The control arm fourth, was standard 14-day LAmB (3 mg/kg/day). All were given with high-dose fluconazole (1200 mg/day). The primary analysis showed that the EFA in all three short-course high-dose arms was noninferior to the control arm. There was no evidence for any dose response effect with additional LAmB doses, suggesting maximal fungicidal activity was achieved with a single 10 mg/kg dose [33] . The AMBI-TION phase III trial is currently comparing a single, high-dose of L-AmB given with 14 days of flucytosine and fluconazole against the current WHO recommended first-line regimen (ISRCTN: 72509687).
Alternative antifungal agents
The recently completed adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis (ASTRO) phase III trial explored the addition of sertraline to standard induction with amphotericin and fluconazole, which had shown some promise in a phase II trial [34] . On the contrary, this trial was stopped after recruiting 460 of a planned 550 patients as there was found to be no impact on mortality [35
&&
]. In an ongoing search for other drugs that could be repurposed, one research team in Vietnam are currently recruiting patients to a phase II trial adding tamoxifen to the standard induction regimen with results expected in 2019. Researchers in the USA have developed a new investigational fungal Cyp51 inhibitor called VT-1129 which has demonstrated potent in vitro activity against cryptococcus [36] . Finally, the antihelmith drug flubendazole has shown potential promise [37] , along with multiple calcium channel blockers demonstrating action against cryptococcus [38] . To date, no clinical trial has been conducted using these agents.
Steroids
The CRYPTODEX placebo-controlled trial investigated the role of adjunctive dexamethasone during the first 6 weeks of cryptococcal meningitis treatment and was conducted in six counties across Africa and Asia [3 && ]. The trial was stopped after the recruitment of 451 patients at the planned mid-point interim analysis which found that steroids did not reduce mortality, significantly increased adverse events and disability, and led to slower rates of decline in EFA. Dexamethasone increased the rate of decline in CSF TNF-a, which could be an explanation for the slower fungal clearance and poor outcomes [39] . Steroids are therefore not a suitable adjunctive treatment during the induction phase, but continue to play a role in the treatment of cryptococcal meningitis immune reconstitution inflammatory syndrome (IRIS) [20 && ].
Neurapheresis
A research group in the USA have recently published a proof of concept using an animal model wherein they filtered cryptococcus out of the CSF of rabbits using a process called neurapheresis [40 & ]. This approach is in its infancy but warrants further exploration.
Therapeutic lumbar punctures
Lumbar punctures are also essential for the recognition and effective management of raised intracranial pressure which is associated with improved outcomes [41] . In many high-burden settings manometers are not reliably available. As an alternative in such settings, one study in South Africa found the optimal cut-off value for defining high pressure using a standard 22-G spinal needle is at least 40 drops/min [42] . In additional to a shortage of equipment, clinicians must often navigate complex cultural barriers to obtaining CSF samples in circumstances, whereby patients refuse lumbar puncture, either for fear of pain -compounded by limited used of local anaesthetic -or concerns that lumbar punctures cause death [43] .
ANTIRETROVIRAL THERAPY AND IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME
IRIS remains a significant complication of cryptococcal meningitis. Individuals presenting with a first episode of cryptococcal meningitis manifesting as an unmasking IRIS may suffer worse outcomes than those who have been ART exposed [44] . A recent Cochrane review has appraised four trials comparing the impact of early ART (within the first 4 weeks of antifungal initiation) compared with delayed ART (after 4 weeks) and has concluded that ART should be delayed until at least 4 weeks due to a potential higher risk of mortality among early initiators [45 && ]. The specific host and pathogen attributes that lead to the development of cryptococcal meningitis-IRIS are still not fully understood. Development of cryptococcal meningitis-IRIS has been strongly associated with high central nervous system (CNS) expression of the chemokines MCP-1(CCL2) and MIP-1a(CCL3) at initial cryptococcal meningitis presentation. It is hypothesized that when immune restoration occurs this leads to an influx of inflammatory cells into the CNS, excessive dysregulated local inflammation and IRIS [46, 47] . A recent study has shown lower levels of plasma IgM antibodies to some of the cryptococcal polysaccharide antigens and total plasma IgM in cases of cryptococcal meningitis-IRIS [48] , although the role of antibody-mediated protection in cryptococcal meningitis remains uncertain. This observation may indicate an important role for antibody-mediated protection during cryptococcal meningitis, and fit with the overarching hypothesis that a poor initial immune response and subsequent failure of effective immune clearance of CrAg are key predisposing factors for IRIS [49] .
ADVOCACY
Increasing access to L-AmB in LMICs will help reduce the drug-induced toxicities encountered with conventional amphotericin B. Gilead have recently announced an expansion of their preferential pricing programme for visceral leishmaniasis to include cryptococcal meningitis which could have a dramatic impact on mortality [50] . In addition the Food and Drug Administration have recently included treatments for cryptococcal meningitis in their priority review voucher scheme which could spur further drug development in this field [51] . Furthermore, despite the strong evidence supporting the use of flucytosine for the treatment of cryptococcal meningitis, flucytosine remains unregistered and unavailable in African and Asian LMICs with very few companies manufacturing the drug. It is hoped that with an increasing acknowledgement of the role of flucytosine its production, registration and distribution will broaden [52] .
CONCLUSION
Cryptococcal meningitis continues to pose a major clinical challenge in resource limited settings. Screening and diagnosis have been revolutionized by the highly sensitive lateral flow assay, and seminal clinical trials have improved our understanding of how to optimize induction therapy, with shorter courses of amphotericin given with flucytosine to reduce mortality rates, and the avoidance of harmful adjunctive steroids. However, advocacy efforts are urgently needed to ensure that patients with cryptococcal meningitis have access to these novel diagnostics and treatments so that recent advances in evidence can be translated into clinical practice.
